Copanlisib (Aliqopa)

Mechanism of action

From NCI Drug Dictionary: A phosphoinositide 3-kinase (PI3K) inhibitor with potential antineoplastic activity. Copanlisib inhibits the activation of the PI3K signaling pathway, which may result in inhibition of tumor cell growth and survival in susceptible tumor cell populations.

Diseases for which it is used

• Follicular lymphoma

History of changes in FDA indication

• 9/14/2017: Granted FDA accelerated approval "for the treatment of adult patients with relapsed follicular lymphoma who have received at least two prior systemic therapies."

Also known as

• Code name: BAY 80-6946
• Brand name: Aliqopa